On rereading the above I find that it’s somewhat misleading. I.e., from a practical standpoint the phase-3 trial in SSP is in almost the same indication as the just-completed phase-2 trial. The phase-2 enrolled only patients experiencing an acute stroke, but the endpoint of consequence was the prevention of a recurrent stroke, which is the definition of SSP.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.